Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Gross Profit (2016 - 2019)

Cardiff Oncology's Gross Profit history spans 7 years, with the latest figure at $92577.0 for Q4 2019.

  • For Q4 2019, Gross Profit rose 18.67% year-over-year to $92577.0; the TTM value through Dec 2019 reached $243137.0, up 210.95%, while the annual FY2019 figure was $244632.0, 211.64% up from the prior year.
  • Gross Profit for Q4 2019 was $92577.0 at Cardiff Oncology, up from $51687.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $92577.0 in Q4 2019 and bottomed at -$3.0 million in Q2 2016.
  • The 5-year median for Gross Profit is -$251200.0 (2017), against an average of -$745205.2.
  • The largest annual shift saw Gross Profit tumbled 2368.35% in 2016 before it surged 139.79% in 2019.
  • A 5-year view of Gross Profit shows it stood at -$115537.0 in 2015, then tumbled by 1845.93% to -$2.2 million in 2016, then soared by 78.47% to -$484011.0 in 2017, then skyrocketed by 116.12% to $78015.0 in 2018, then grew by 18.67% to $92577.0 in 2019.
  • Per Business Quant, the three most recent readings for CRDF's Gross Profit are $92577.0 (Q4 2019), $51687.0 (Q3 2019), and $36852.0 (Q2 2019).